Nataly Tarasenko Felsenstein Medical Research Center Biography Publications Institution JoVE Articles Nataly Tarasenko has not added a biography. If you are Nataly Tarasenko and would like to personalize this page please email our Author Liaison for assistance. Publications Palbociclib in Combination with Sunitinib Exerts a Synergistic Anti-cancer Effect in Patient-derived Xenograft Models of Various Human Cancers Types Cancer Letters. Jun, 2022 | Pubmed ID: 35358627 Valproic Acid Prodrug Affects Selective Markers, Augments Doxorubicin Anticancer Activity and Attenuates Its Toxicity in a Murine Model of Aggressive Breast Cancer Pharmaceuticals (Basel, Switzerland). Nov, 2021 | Pubmed ID: 34959644 The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model International Journal of Molecular Sciences. Feb, 2019 | Pubmed ID: 30736437 Comparison of the Anticancer Properties of a Novel Valproic Acid Prodrug to Leading Histone Deacetylase Inhibitors Journal of Cellular Biochemistry. Apr, 2018 | Pubmed ID: 29135083 AN-7, a Butyric Acid Prodrug, Sensitizes Cutaneous T-cell Lymphoma Cell Lines to Doxorubicin Via Inhibition of DNA Double Strand Breaks Repair Investigational New Drugs. Feb, 2018 | Pubmed ID: 28884410 Effects of Histone Deacetylase Inhibitory Prodrugs on Epigenetic Changes and DNA Damage Response in Tumor and Heart of Glioblastoma Xenograft Investigational New Drugs. Aug, 2017 | Pubmed ID: 28315153 Bi-functional Prodrugs of 5-aminolevulinic Acid and Butyric Acid Increase Erythropoiesis in Anemic Mice in an Erythropoietin-independent Manner European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences. Aug, 2016 | Pubmed ID: 27283485 The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin PloS One. 2016 | Pubmed ID: 26752418 A Novel Valproic Acid Prodrug As an Anticancer Agent That Enhances Doxorubicin Anticancer Activity and Protects Normal Cells Against Its Toxicity in Vitro and in Vivo Biochemical Pharmacology. Mar, 2014 | Pubmed ID: 24463168 Unterschiedliche Wirkung Von Butyroyloxymethyl Diethylphosphate (AN-7), Ein Histon Deacetylase Inhibitor Und Doxorubicin Bei Mäusen Mit Einen Mamma-Tumor PloS One. 2012 | Pubmed ID: 22384017 Histon Deacetylase Inhibitor Butyroyloxymethyl Diethylphosphate (AN-7) Schützt Normale Zellen Gegen Toxizität Der Anti-Krebs-Agents Und Vermehren Ihre Krebsbekämpfende Aktivität Investigational New Drugs. Feb, 2012 | Pubmed ID: 20862515 Gamma-aminobutyric Acid Amides of Nortriptyline and Fluoxetine Display Improved Pain Suppressing Activity Journal of Medicinal Chemistry. May, 2009 | Pubmed ID: 19378992 Histone Deacetylase Inhibitors: the Anticancer, Antimetastatic and Antiangiogenic Activities of AN-7 Are Superior to Those of the Clinically Tested AN-9 (Pivanex) Clinical & Experimental Metastasis. 2008 | Pubmed ID: 18506586 The Selectivty and Anti-metastatic Activity of Oral Bioavailable Butyric Acid Prodrugs Investigational New Drugs. Sep, 2006 | Pubmed ID: 16502348 Etablierung von 3-dimensionalen Sphäroiden aus patienteneigenen Tumorproben und Bewertung ihrer Empfindlichkeit gegenüber Medikamenten Neta Moskovits1,2, Ella Itzhaki1,2, Nataly Tarasenko1,2, Eva Chausky1,2, Avital Bareket-Samish3, Aleksandr Kaufman1,2, Raisa Meerson1,2, Salomon M. Stemmer1,2,4 1Felsenstein Medical Research Center, 2Davidoff Center, Rabin Medical Center, 3BioInsight Ltd., 4Sackler Faculty of Medicine, Tel Aviv University JoVE 64564 Ricerca sul cancro
Etablierung von 3-dimensionalen Sphäroiden aus patienteneigenen Tumorproben und Bewertung ihrer Empfindlichkeit gegenüber Medikamenten Neta Moskovits1,2, Ella Itzhaki1,2, Nataly Tarasenko1,2, Eva Chausky1,2, Avital Bareket-Samish3, Aleksandr Kaufman1,2, Raisa Meerson1,2, Salomon M. Stemmer1,2,4 1Felsenstein Medical Research Center, 2Davidoff Center, Rabin Medical Center, 3BioInsight Ltd., 4Sackler Faculty of Medicine, Tel Aviv University JoVE 64564 Ricerca sul cancro